Morgan Stanley Cyteir Therapeutics, Inc. Transaction History

Morgan Stanley

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$2.84 - $3.13 $2,840 - $3,130	1,000 New	1,000 $3,000
Q3 2023 Nov 15, 2023	SELL	$2.71 - $2.84 $13,474 - $14,120	-4,972 Reduced 83.26%	1,000 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.74 - $2.6 $207,461 - $310,000	-119,231 Reduced 95.23%	5,972 $15,000
Q1 2023 May 15, 2023	BUY	$1.47 - $1.84 $139,548 - $174,673	94,931 Added 313.59%	125,203 $227,000
Q4 2022 Feb 14, 2023	SELL	$1.18 - $1.76 $46,093 - $68,749	-39,062 Reduced 56.34%	30,272 $49,000
Q3 2022 Nov 14, 2022	SELL	$1.99 - $4.05 $290,617 - $591,457	-146,039 Reduced 67.81%	69,334 $133,000
Q2 2022 Oct 27, 2022	BUY	$1.62 - $4.4 $90,757 - $246,501	56,023 Added 35.16%	215,373 $645,000
Q2 2022 Aug 15, 2022	BUY	$1.62 - $4.4 $90,757 - $246,501	56,023 Added 35.16%	215,373 $645,000
Q1 2022 Oct 27, 2022	SELL	$3.39 - $10.51 $189,917 - $588,801	-56,023 Reduced 26.01%	159,350 $600,000
Q1 2022 May 13, 2022	BUY	$3.39 - $10.51 $244,619 - $758,391	72,159 Added 82.76%	159,350 $600,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $825,739 - $1.61 Million	84,002 Added 2634.12%	87,191 $992,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $46,463 - $69,711	3,189 New	3,189 $56,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.